Literature DB >> 28300544

Pre-analytical and analytical aspects affecting clinical reliability of plasma glucose results.

Sara Pasqualetti1, Federica Braga2, Mauro Panteghini2.   

Abstract

The measurement of plasma glucose (PG) plays a central role in recognizing disturbances in carbohydrate metabolism, with established decision limits that are globally accepted. This requires that PG results are reliable and unequivocally valid no matter where they are obtained. To control the pre-analytical variability of PG and prevent in vitro glycolysis, the use of citrate as rapidly effective glycolysis inhibitor has been proposed. However, the commercial availability of several tubes with studies showing different performance has created confusion among users. Moreover, and more importantly, studies have shown that tubes promptly inhibiting glycolysis give PG results that are significantly higher than tubes containing sodium fluoride only, used in the majority of studies generating the current PG cut-points, with a different clinical classification of subjects. From the analytical point of view, to be equivalent among different measuring systems, PG results should be traceable to a recognized higher-order reference via the implementation of an unbroken metrological hierarchy. In doing this, it is important that manufacturers of measuring systems consider the uncertainty accumulated through the different steps of the selected traceability chain. In particular, PG results should fulfil analytical performance specifications defined to fit the intended clinical application. Since PG has tight homeostatic control, its biological variability may be used to define these limits. Alternatively, given the central diagnostic role of the analyte, an outcome model showing the impact of analytical performance of test on clinical classifications of subjects can be used. Using these specifications, performance assessment studies employing commutable control materials with values assigned by reference procedure have shown that the quality of PG measurements is often far from desirable and that problems are exacerbated using point-of-care devices.
Copyright © 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analytical performance specifications; EQAS; Glucose; Standardization; Uncertainty

Mesh:

Substances:

Year:  2017        PMID: 28300544     DOI: 10.1016/j.clinbiochem.2017.03.009

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Effects of different tube types on patient classification using current diabetes decision limits.

Authors:  Matthias Orth; Hannes Hawran; Jagadish Ulloor; Kiran Bachhawat; Lieselotte Lennartz
Journal:  Pract Lab Med       Date:  2019-09-19

Review 2.  Biological variation: Understanding why it is so important?

Authors:  Tony Badrick
Journal:  Pract Lab Med       Date:  2021-01-04

3.  Effect of Sample Volume Variation and Delay in Analysis on Plasma Glucose Concentration in Sri Lankan Healthy Adults.

Authors:  Isuru Anupama Dharmasena; Deepani Siriwardhana; Anoja Priyadarshani Attanayake
Journal:  Scientifica (Cairo)       Date:  2021-01-15

Review 4.  Glucose biosensors in clinical practice: principles, limits and perspectives of currently used devices.

Authors:  Salvatore Andrea Pullano; Marta Greco; Maria Giovanna Bianco; Daniela Foti; Antonio Brunetti; Antonino S Fiorillo
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

5.  Glucose meters: What's the laboratory reference glucose?

Authors:  Mariarosa Carta; Davide Giavarina; Andreina Paternoster; Graziella Bonetti
Journal:  J Med Biochem       Date:  2020-01-10       Impact factor: 3.402

6.  Preanalytical issues related to routine and diagnostic glucose tests: Results from a survey in Spain.

Authors:  Isabel García-Del-Pino; Josep M Bauça; Carolina Gómez; Andrea Caballero; María Antonia Llopis; Mercedes Ibarz; Débora Martínez; Montserrat Ventura; Itziar Marzana; Juan J Puente; Marta Segovia; Paloma Salas; Rubén Gómez-Rioja
Journal:  Biochem Med (Zagreb)       Date:  2019-12-15       Impact factor: 2.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.